San Diego, California, Feb 23, 2024 – GluBio Therapeutics Inc., a clinical-stage, TPD-focused biotech company announced the successful completion of the first Safety Review Committee (SRC) meeting for phase 1 clinical trial of GLB-002, a next-generation IKZF1/3 selective molecular glue degrader, in patients with relapsed or refractory non-Hodgkin lymphoma (R/R NHL). In cohort 1, GLB-002 exhibited excellent pharmacokinetics, pharmacodynamics, safety and tolerability, and achieved the expected extent of IKZF1/3 degradation. The cohort 2 is now open for patient recruitment, which marks the entry of this clinical trial into a new stage. “We are very delighted that we have successfully completed the dosing and Dose Limiting Toxicities ( DLT ) observation for cohort 1 within 2 months of study kickoff for the GLB-002 phase 1 study, to begin evaluating its safety and preliminary efficacy at the next dose level.” said Gang Lu, Ph.D., Founder, President and CEO of GluBio Therapeutics, “GLB-002 is